Serpentine Fibula Polycystic Kidney Syndrome

Serpentine fibula–polycystic kidney syndrome is a very rare genetic condition that mainly affects bones and kidneys. People have curved “S-shaped” fibula bones in the lower legs, multiple cysts in the kidneys, and often distinctive facial and skull features. Over time, bone strength may be poor, and there can be other changes in teeth, spine, and joints. Many experts now group SFPKS within the Hajdu-Cheney syndrome (HCS) spectrum, because both conditions are caused by changes in the same gene (NOTCH2) and share many features. PMCPubMedMedlinePlus

Serpentine fibula–polycystic kidney syndrome is a very rare genetic condition that affects the bones and the kidneys. Children are often short in height and have leg bones called fibulas that are very long and curved like an “S.” The arms or legs may bow. The skull can show extra tiny bones (wormian bones), and the overall bones can be weak (osteoporosis) with risk of fractures. The kidneys slowly develop many cysts, which can lead to high blood pressure and kidney problems over time. SFPKS is now understood to sit on the same spectrum as Hajdu-Cheney syndrome, and both are usually caused by changes (truncating variants) in a gene called NOTCH2, which helps control bone and kidney development. PubMed+1SpringerLinkMedlinePlusBioMed Central

---

Other names

SFPKS has been reported under several overlapping labels because it shares many features with Hajdu-Cheney syndrome (HCS). You may see: “serpentine fibula–polycystic kidneys syndrome,” “Exner syndrome,” “Hajdu-Cheney spectrum with serpentine fibulae,” or older descriptions such as “acro-osteolysis with osteoporosis and craniofacial changes” when cystic kidneys are present. Historically, some cases were misclassified as Melnick-Needles syndrome or discussed alongside Alagille-spectrum disorders because the same developmental pathway (Notch signaling) is involved. Modern genetics shows that SFPKS and HCS share NOTCH2 mutations and are best viewed as variants of one disorder rather than two completely separate diseases. MedlinePlusorpha.netSpringerLink

---

Types

There is no single, universally accepted list of “official subtypes.” Clinicians instead use practical groupings that reflect how the condition shows up in real life:

1. Classic SFPKS phenotype. Marked S-shaped fibulae, bowed forearms/legs, osteoporosis or fractures, and polycystic kidneys recognized in childhood. SpringerLink+1

2. Hajdu-Cheney spectrum with renal cysts. Individuals who meet broader HCS features (acro-osteolysis, wormian bones, facial traits) and also have renal cysts; genetics confirms a truncating NOTCH2 variant. PubMedMedlinePlus

3. Prenatal-onset presentation. Curved long bones and abnormal kidneys suspected on fetal ultrasound or MRI; postnatal imaging confirms S-shaped fibulae and renal cysts. PubMed

4. Familial vs. de novo. Most reported cases are de novo (new in the child), but autosomal-dominant inheritance can occur when a parent carries the variant. PubMed

---

Causes

1) NOTCH2 truncating variant (primary cause). Most proven cases carry a heterozygous truncating mutation in the last exon of NOTCH2, leading to overactive Notch signaling in bone and kidney development. PubMed

2) Notch-pathway dysregulation. Abnormal Notch signaling disrupts bone remodeling (favoring bone loss) and kidney tubule development (favoring cyst formation). BioMed Central

3) Autosomal-dominant effect. A single altered NOTCH2 copy is sufficient to cause disease features. MedlinePlus

4) De novo mutation. Many patients have a new mutation not present in either parent. PubMed

5) HCS–SFPKS shared etiology. Clinical overlap reflects the shared NOTCH2 mechanism; historically separated labels describe one spectrum. MedlinePlusWiley Online Library

6) Prenatal developmental impact. Notch signaling guides skeletal patterning and nephron/tubule formation, so disruption during fetal life shapes the phenotype. BioMed Central

7) Bone remodeling imbalance. Notch activation can tilt osteoclast/osteoblast activity toward bone loss, causing osteoporosis and fractures. BioMed Central

8) Long-bone modeling defects. Abnormal growth plate signaling yields elongated, bowed, “serpentine” fibulae and bowed radii. SpringerLink

9) Cranial suture ossification changes. Disturbed intramembranous ossification contributes to wormian bones and skull shape differences. HNL Lab Medicine

10) Renal cystogenesis. Disrupted tubular differentiation and signaling promotes multiple kidney cysts and later kidney dysfunction. PubMed

11) Connective-tissue weakness. Mild facial dysmorphism, hernias, and chest wall shape may reflect generalized connective-tissue effects within the pathway. WikipediaHNL Lab Medicine

12) Hearing-related skeletal changes. Craniofacial and ossicular involvement can lead to conductive hearing loss. HNL Lab Medicine

13) Overlap with Alagille-spectrum biology. Rare NOTCH2 variants are reported in atypical Alagille presentations, underscoring shared pathway risk, though classic Alagille is usually JAG1-related. Wiley Online Library

14) Growth-plate vulnerability. Abnormal signaling at the physes contributes to short stature. SpringerLink

15) Fracture susceptibility. Osteoporosis plus long-bone bowing increases mechanical stress and fracture risk. HNL Lab Medicine

16) Dental and mandibular effects (HCS spectrum). Some patients show jaw and tooth changes analogous to HCS due to shared genetics. MedlinePlus

17) Variability from genetic background. Expressivity differs among families; the same NOTCH2 class of variant can produce a range of bone–kidney severity. (Inference from spectrum literature.) ScienceDirect

18) Mosaicism in a parent (occasionally). Very rare parental mosaicism can explain recurrence with apparently unaffected parents. (General principle in dominant genetic disorders; consider in counseling.)

19) Environmental stresses on weak bone. Low vitamin D, low calcium intake, or immobility can aggravate underlying osteoporosis (modifier, not a root cause).

20) Secondary renal stresses. High salt intake, poorly controlled blood pressure, or nephrotoxic drugs can accelerate kidney decline in a cystic kidney (modifier).

Items are practical modifiers seen in many genetic bone-kidney conditions; the proven root driver remains NOTCH2 pathway disruption. PubMedBioMed Central

---

Common symptoms and signs

1. Short height: the child grows more slowly than peers. SpringerLink

2. Curved “S-shaped” fibulae: the outer lower-leg bones look long and wavy on X-ray; legs may bow. SpringerLink

3. Bowed forearms or legs: visible curve of the radius/ulna or tibia/fibula. SpringerLink

4. Bone fragility and fractures: bones break more easily with minor falls. HNL Lab Medicine

5. Osteoporosis: low bone density on scans. HNL Lab Medicine

6. Skull differences with wormian bones: tiny extra bones seen on skull imaging. HNL Lab Medicine

7. Facial traits: small jaw, prominent forehead or brows, large corneas in some, producing an unusual facial appearance. Wikipediaaccessanesthesiology.mhmedical.com

8. Hernias: umbilical or inguinal bulges since infancy. Wikipedia

9. Chest shape changes: mild sunken chest in some children. Wikipedia

10. Polycystic kidneys: often silent at first; later, frequent urination, flank fullness, or urinary findings. PubMed

11. High blood pressure: develops as kidney cysts enlarge. PubMed

12. Hearing problems: conductive hearing loss or recurrent ear issues. HNL Lab Medicine

13. Motor delays: sitting, standing, or walking may be slightly delayed due to limb bowing and muscle weakness. HNL Lab Medicine

14. Foot positioning (metatarsus adductus): inward curving of the forefoot. SpringerLink

15. Dental/jaw differences (spectrum): HCS-like jaw changes can appear. MedlinePlus

---

Diagnostic tests

A) Physical-exam based

1) Full growth and body-proportion exam. The clinician measures height, arm span, upper-to-lower segment ratio, and head size to document short stature and limb disproportions. This baseline helps track change over time. SpringerLink

2) Musculoskeletal inspection and gait. Visual exam of standing and walking shows bowing, knee/ankle alignment, and functional limits that guide bracing or surgery. SpringerLink

3) Skin and hernia check. The abdomen and groins are checked for umbilical/inguinal hernias caused by connective-tissue weakness. Wikipedia

4) Blood pressure measurement. Routine BP screening looks for early hypertension due to kidney cysts. PubMed

5) Ear, nose, and throat exam. Middle-ear status and palate/jaw structure (e.g., Pierre-Robin sequence) are assessed because they relate to feeding, speech, and hearing. HNL Lab Medicine

B) Manual/bedside tests

6) Limb-alignment measurements. Tape or goniometer measurements (inter-malleolar distance, tibio-femoral angle) quantify bowing to decide on bracing vs. osteotomy.

7) Range-of-motion testing. Gentle joint movement testing identifies contractures or compensatory stiffness that may need physiotherapy.

8) Palpation/percussion of kidneys. In thin children, a clinician may feel enlarged kidneys or note flank fullness, prompting imaging.

9) Functional motor testing. Timed up-and-go, single-leg stance, and stair tests track balance and strength over visits.

10) Hearing screening (manual bedside). Whisper-voice or tuning-fork (Rinne/Weber) tests suggest conductive hearing loss, guiding audiology.

C) Laboratory and pathological tests

11) Serum creatinine with eGFR. Estimates kidney filtering capacity; rising creatinine or falling eGFR suggests cyst-related decline. PubMed

12) Urinalysis and urine albumin-to-creatinine ratio. Detects blood or protein leakage from cystic kidneys before symptoms are obvious. PubMed

13) Electrolytes, calcium, phosphate, alkaline phosphatase, PTH, and vitamin D. Profiles bone metabolism and secondary effects from kidney disease; helps treat osteoporosis safely. BioMed Central

14) Bone-turnover markers (optional). Markers like P1NP or CTX can help specialists monitor bone loss in severe cases. BioMed Central

15) NOTCH2 genetic testing (sequencing with deletion/duplication analysis). Confirms the diagnosis; many patients have truncating variants in the last exon. Test parents to check if the variant is new or inherited. PubMed

16) Prenatal genetic testing (when indicated). If a familial variant is known, chorionic villus sampling or amniocentesis can test the fetus for the same NOTCH2 change. PubMed

D) Electrodiagnostic/physiologic tests

17) Audiology with tympanometry and auditory brainstem responses (ABR). Defines the degree and type of hearing loss (conductive vs. sensorineural) and guides tubes, hearing aids, or surgery. HNL Lab Medicine

18) Electrocardiogram (ECG) before major procedures. Some children may have heart differences within the broader spectrum; ECG helps peri-anesthetic planning even if echocardiogram is normal. PMC

E) Imaging tests

19) Skeletal survey (plain X-rays). Confirms long, serpentine fibulae; shows bowed radii/ulnae, vertebral and skull changes, and helps track fractures or healing. SpringerLinkaccessanesthesiology.mhmedical.com

20) Dual-energy X-ray absorptiometry (DXA). Measures bone density to diagnose osteoporosis and monitor therapy response. HNL Lab Medicine

21) Renal ultrasound. First-line, radiation-free test to detect kidney size and cysts; useful for routine follow-up. PubMed

22) Renal MRI (or CT when needed). Maps cyst number and size in detail and evaluates complications; MRI is preferred to avoid radiation. PubMed

23) Prenatal ultrasound and, selectively, fetal MRI. May show curved long bones and cystic kidneys before birth in families at risk. PubMed

24) Temporal-bone CT (when hearing loss is complex). Looks for ossicular or middle-ear structural issues that may be surgically correctable. HNL Lab Medicine

25) Echocardiography (as clinically indicated). Screens for congenital heart differences mentioned in spectrum reports when exam or history suggests them. PMC

Non-pharmacological treatments

Physiotherapy

1. Gentle range-of-motion for ankles and knees
   Purpose: keep joints supple around bowed fibula/tibia. Mechanism: slow stretch of capsule and muscles reduces stiffness and compensatory gait strain. Benefits: easier walking, less pain, fewer contractures.

2. Progressive muscle strengthening (hips, thighs, calves)
   Purpose: support weak bones with stronger muscles. Mechanism: low-load, high-repetition resistance builds endurance without high impact. Benefits: better stability, fewer falls, less knee/ankle stress.

3. Core and postural training
   Purpose: protect the spine (kyphosis/scoliosis risk). Mechanism: activates deep trunk muscles to share load with spine. Benefits: improved balance and breathing mechanics; reduced back pain.

4. Gait training with assistive devices (as needed)
   Purpose: safer walking; correct limp due to leg bowing. Mechanism: canes/walkers shift part of ground-reaction forces. Benefits: fewer falls, more stamina for daily tasks.

5. Aquatic therapy
   Purpose: exercise without impact. Mechanism: buoyancy unloads joints while water resistance strengthens. Benefits: fitness gains with low fracture risk.

6. Low-impact aerobic conditioning (cycle/elliptical)
   Purpose: heart-kidney health and stamina. Mechanism: moderate intensity boosts VO₂ and endothelial function. Benefits: blood-pressure support, weight control, mood lift.

7. Ankle-foot orthoses (AFO) fitting and training
   Purpose: stabilize ankle with curved fibula. Mechanism: rigid/hinged brace aligns joint and limits unsafe motion. Benefits: steadier steps, less fatigue.

8. Balance/vestibular practice
   Purpose: prevent falls in osteoporosis. Mechanism: challenges proprioception safely. Benefits: fewer injuries, confidence in mobility.

9. Stretching program (hamstrings, calves, hip flexors)
   Purpose: reduce muscle tightness from altered gait. Mechanism: viscoelastic change with sustained stretch. Benefits: longer stride, less knee pain.

10. Breathing and rib mobility techniques
    Purpose: help if chest shape limits expansion. Mechanism: diaphragmatic drills and thoracic mobility. Benefits: easier activity, less dyspnea.

11. Functional task training (sit-to-stand, stairs)
    Purpose: independence in daily life. Mechanism: task-specific motor learning. Benefits: safer transfers, quicker routines.

12. Spinal protection education
    Purpose: avoid excessive neck flexion/extension if basilar invagination risk. Mechanism: movement substitution and ergonomics. Benefits: lowers neurological risk.

13. Pain-modulating modalities (heat/cold/TENS)
    Purpose: reduce soreness without pills. Mechanism: gate-control and local circulation effects. Benefits: more comfortable therapy sessions.

14. Fracture-safe loading program
    Purpose: stimulate bone where safe. Mechanism: supervised, graded compressive loads per DXA status. Benefits: maintains function while minimizing risk. BioMed Central

15. Custom footwear/orthotics
    Purpose: distribute plantar pressure in short/broad toes and foot deformity. Mechanism: arch support, heel stabilization. Benefits: fewer calluses, better endurance.

Mind-Body, “Gene,” and Educational therapies

16. Pain-coping skills training
    Purpose: manage chronic musculoskeletal pain. Mechanism: CBT and pacing reduce central sensitization. Benefits: better function with less medication.

17. Sleep hygiene coaching
    Purpose: improve recovery and pain control. Mechanism: regular schedule, light control, stimulus restriction. Benefits: energy, mood, and pain thresholds improve.

18. Nutrition education (kidney- and bone-friendly)
    Purpose: support BP, bone, and kidney health. Mechanism: adequate calcium/vitamin D; DASH-style sodium limits; hydration balance as advised by nephrology. Benefits: steadier BP, better mineral balance.

19. Falls-prevention home review
    Purpose: remove hazards. Mechanism: lighting, rails, non-slip mats. Benefits: lower fracture risk.

20. Genetic counseling (family planning & testing)
    Purpose: explain inheritance and options. Mechanism: risk assessment, cascade testing. Benefits: informed choices for relatives. MedlinePlus

21. Education on medication safety
    Purpose: avoid kidney-toxic or bone-harmful drugs. Mechanism: pharmacist review of NSAIDs, high-dose steroids, etc. Benefits: fewer complications.

22. Mindfulness/relaxation/slow breathing
    Purpose: reduce sympathetic drive and pain. Mechanism: vagal activation; improved pain tolerance. Benefits: calmer mood, lower perceived pain.

23. School/work accommodation planning
    Purpose: maintain participation. Mechanism: seating, lifting limits, rest breaks. Benefits: attendance and quality of life.

24. Post-op rehab playbook (if surgeries planned)
    Purpose: smooth recovery. Mechanism: early protected mobilization, bone-safe loading. Benefits: fewer complications.

25. Patient-support networking
    Purpose: reduce isolation in rare disease. Mechanism: connect with HCS/SFPKS communities. Benefits: shared strategies and resources. National Organization for Rare Disorders

---

Drug treatments

Important: there is no approved drug proven to modify SFPKS/HCS itself; choices below target bone health, pain, BP, and kidney or dental/ENT issues. Doses are typical adult ranges and must be individualized by your clinicians, especially with kidney disease. Evidence for anti-osteoporotic benefit in HCS is limited/uncertain. BioMed Central

1. Alendronate (bisphosphonate)
   Class: anti-resorptive. Dose/time: 70 mg orally once weekly. Purpose: reduce fracture risk in osteoporosis. Mechanism: inhibits osteoclasts. Side effects: GI upset, esophagitis; rare ONJ/atypical femur fractures.

2. Zoledronic acid (bisphosphonate, IV)
   Dose: 5 mg IV once yearly. Purpose: osteoporosis when oral agents not tolerated. Mechanism: potent osteoclast inhibition. Side effects: flu-like reaction, hypocalcemia; avoid if severe CKD.

3. Denosumab
   Class: RANKL antibody. Dose: 60 mg SC every 6 months. Purpose: anti-resorptive alternative. Mechanism: blocks osteoclast formation. Side effects: hypocalcemia, rebound bone loss if stopped; ONJ risk.

4. Teriparatide
   Class: PTH(1-34) anabolic. Dose: 20 mcg SC daily up to 24 months. Purpose: increase bone formation (selected cases). Mechanism: stimulates osteoblasts. Side effects: hypercalcemia, dizziness; avoid in high bone-turnover states or certain cancers; use cautiously.

5. Romosozumab
   Class: sclerostin antibody. Dose: 210 mg SC monthly for 12 months. Purpose: anabolic/anti-resorptive bridge. Mechanism: increases formation, decreases resorption. Side effects: possible increased cardiovascular risk; hypocalcemia.

6. Calcitonin (nasal or SC)
   Purpose: short-term pain control after vertebral fracture. Mechanism: reduces osteoclast activity; analgesic effect. Side effects: nausea, flushing; limited long-term benefit.

7. Cholecalciferol (vitamin D3)
   Dose: individualized (e.g., 800–2000 IU/day) per labs. Purpose: maintain 25-OH-D for bone and muscle. Mechanism: aids calcium absorption. Side effects: hypercalcemia if excessive.

8. Calcium (diet first; supplement if needed)
   Dose: typically 1000–1200 mg/day total intake. Purpose: mineral supply for bone. Mechanism: supports remodeling. Side effects: constipation; kidney stone risk if excess and not balanced with fluids/Vit D.

9. Acetaminophen (paracetamol)
   Dose: up to 3 g/day (renal/hepatic limits apply). Purpose: pain relief safer for kidneys than many NSAIDs. Mechanism: central COX modulation. Side effects: liver toxicity if overdosed.

10. Topical NSAIDs (e.g., diclofenac gel)
    Purpose: localized pain with less systemic exposure. Mechanism: local COX inhibition. Side effects: skin irritation; still use carefully with CKD.

11. ACE inhibitor (e.g., lisinopril) or ARB (e.g., losartan)
    Purpose: control BP and reduce kidney protein leak. Mechanism: RAAS blockade. Side effects: cough (ACEi), high potassium, kidney function changes—monitoring needed.

12. Tolvaptan (specialist use in ADPKD-like disease)
    Purpose: slow cyst growth in selected adult patients with rapidly progressive autosomal dominant PKD; not routine for SFPKS, but nephrologists may consider if phenotype matches. Mechanism: V2-receptor antagonism lowers cAMP. Side effects: thirst, frequent urination; liver toxicity monitoring mandatory. (Decision is highly individualized by nephrology.)

13. Loop diuretics (e.g., furosemide)
    Purpose: edema/BP control in CKD with volume overload. Mechanism: blocks Na-K-2Cl in loop of Henle. Side effects: electrolyte loss, dehydration, ototoxicity at high IV doses.

14. Antibiotics (culture-guided)
    Purpose: treat recurrent respiratory, dental, or urinary infections. Mechanism: pathogen-specific. Side effects: drug-specific; adjust for renal function.

15. Proton-pump inhibitor (short courses when needed)
    Purpose: protect stomach if short NSAID use is unavoidable. Mechanism: blocks acid secretion. Side effects: hypomagnesemia, C. difficile risk with chronic use—prefer minimal duration.

---

Dietary molecular / supportive supplements

(Use only with your clinicians—especially with kidney disease.)

1. Vitamin D3 – see drug section. Supports calcium absorption; low levels worsen bone weakness.

2. Calcium (diet-first) – food sources preferred; supplement only to close gaps.

3. Protein at adequate levels – supports muscle/bone repair; avoid very high protein if kidney function declines.

4. Omega-3 fatty acids – may aid BP and inflammation; fish intake or capsules (renal-safe doses).

5. Magnesium (if low) – muscle/nerve function and bone matrix; monitor in CKD.

6. Vitamin K2 (MK-7) – helps carboxylate bone proteins; evidence emerging; avoid high doses with anticoagulants.

7. Phosphate balance – dietitian-guided if CKD advances; excess phosphate harms bone/mineral balance.

8. CoQ10 – sometimes used for BP/supportive energy in CKD; evidence modest.

9. Citrus/alkali foods – may reduce stone risk and help acid-base balance; check with nephrology.

10. Sodium restriction – not a pill, but powerful: DASH-style intake helps BP and kidney protection.

---

Regenerative / stem-cell

• There is no approved gene therapy, stem-cell cure, or immune “booster” for SFPKS/HCS. Research on NOTCH signaling shows why this is difficult: the pathway is fundamental in many tissues, and “turning it down” safely is complex. Any “regenerative” option should be trial-based only. BioMed Central

1. Romosozumab (bone anabolic/anti-resorptive) – increases bone formation; cardiovascular risk warning; specialist decision only.

2. Teriparatide / Abaloparatide (anabolic peptides) – may help select osteoporotic patients; careful selection and duration limits.

3. Denosumab (RANKL blockade) – potent anti-resorptive; rebound risk on stopping.

4. Experimental MSC therapies – investigational; no proven benefit for SFPKS/HCS.

5. NOTCH-pathway modulators – preclinical concepts; not available for clinical SFPKS/HCS.

6. CRISPR-style gene editing – theoretical at present; not in clinical use for NOTCH2 disorders.

---

Surgeries

1. Long-bone osteotomy/realignment and intramedullary rodding – to correct severe bowing of fibula/tibia/femur, improve alignment, reduce pain, and improve gait.

2. Spine/cranio-cervical decompression and stabilization – for basilar invagination or severe spinal compromise to protect brainstem/spinal cord and relieve symptoms. BioMed Central

3. Dental/maxillofacial procedures – address malocclusion, tooth loss, and periodontal disease to maintain chewing and nutrition. BioMed Central

4. Hernia repair – inguinal/umbilical hernias reported in the spectrum; repair to prevent incarceration. PMC

5. Kidney transplantation (advanced failure) – standard option if kidneys fail; dialysis as bridge as per nephrology practice.

---

Prevention & self-care tips

1. Fall-proof your home and use assistive devices as advised.

2. Keep vaccines current to lower respiratory and ENT infection risk.

3. Practice dental hygiene and regular dentist visits.

4. Follow a DASH-style, lower-salt eating plan for kidney/BP.

5. Avoid smoking and limit alcohol.

6. Avoid unnecessary high-dose steroids (worsen bone) and nephrotoxins (e.g., NSAIDs without guidance, contrast dyes).

7. Maintain vitamin D and calcium within safe ranges.

8. Build a low-impact exercise routine.

9. Monitor BP at home if advised.

10. Keep a rare-disease “summary letter” for emergencies (key risks, cervical spine cautions).

---

When to see doctors urgently

• New or worsening neck pain, severe headaches, visual changes, imbalance, fainting, breathing pauses (possible cranio-cervical complications). BioMed Central

• Sudden severe bone pain, suspected fracture, or new limb weakness.

• Swelling of legs, very high BP, reduced urine or signs of kidney infection (fever, flank pain).

• Rapid dental or gum problems, recurring ear/sinus infections, or hearing loss.

---

What to eat and what to avoid

Eat more of:

1. Calcium-rich foods (dairy/fortified alternatives) within dietitian targets.

2. Vitamin-D sources (fatty fish, fortified foods).

3. Fruits/vegetables (DASH style), especially potassium-appropriate if CKD advances.

4. Lean proteins (fish, poultry, legumes) in amounts tailored to kidney function.

5. Whole grains and healthy fats (olive oil, nuts).

Avoid/limit:

1. Excess salt/sodium (drives BP).
2. Sugary drinks/ultra-processed foods.
3. High-dose NSAIDs without nephrology guidance.
4. Smoking and heavy alcohol.
5. Very high-impact sports if your team has advised fracture precautions.

---

FAQs

1) Is SFPKS a separate disease?
Most experts consider it part of the Hajdu-Cheney syndrome spectrum due to the same NOTCH2 gene changes. PMCMedlinePlus

2) How is it inherited?
Autosomal dominant; many cases arise de novo. MedlinePlus

3) What gene is involved?
NOTCH2, often changes that remove its “off-switch” (PEST domain), keeping signaling active. BioMed Central

4) Can ultrasound detect it before birth?
Sometimes—bowed long bones and cystic kidneys may be seen; confirmation after birth and with genetic testing is needed. PubMed

5) Is intelligence affected?
Reports vary; normal intelligence is documented in SFPKS/HCS, though learning support may help some. PubMed

6) What are the most serious risks?
Cranio-cervical complications (platybasia/basilar invagination) and osteoporosis-related fractures; kidney issues in some. BioMed Central

7) Is there a cure?
No cure yet; care is supportive and preventive. BioMed Central

8) Do bone drugs work?
They’re used case-by-case, but clear, consistent benefit in HCS hasn’t been firmly proven; specialists weigh risks/benefits. BioMed Central

9) Could tolvaptan help kidney cysts?
It’s approved for rapidly progressive ADPKD, not specifically for SFPKS; nephrologists may consider only if the kidney picture fits that profile. (Specialist decision.)

10) What activities are safest?
Low-impact: swimming, cycling, walking programs with physio guidance.

11) What about dental care?
Early, regular dental care prevents tooth loss and supports nutrition. BioMed Central

12) Are hearing issues part of it?
Yes, some people have hearing loss; audiology checks help. BioMed Central

13) Can family members be tested?
Yes—cascade testing after a pathogenic NOTCH2 variant is found. MedlinePlus

14) What specialists should follow me?
Genetics, orthopedics, nephrology, dentistry/ENT, neurosurgery/spine (if indicated), physio, pain/rehab.

15) Where can I learn more?
See MedlinePlus Genetics, Orphanet (Hajdu-Cheney), and peer-reviewed reviews/case series listed in the citations below. MedlinePlusOrpha.net

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 05, 2025.